ERAS Relative Valuation - Erasca Inc - Alpha Spread

Erasca Inc
NASDAQ:ERAS

Watchlist Manager
Erasca Inc Logo
Erasca Inc
NASDAQ:ERAS
Watchlist
Price: 2.94 USD 1.73% Market Closed
Market Cap: 802.1m USD
Have any thoughts about
Erasca Inc?
Write Note

Relative Value

There is not enough data to reliably calculate the relative value of ERAS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ERAS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.7
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-4.2
Industry
23.9
Forward
-3.3
vs History
vs Industry
Median 3Y
-6.7
Median 5Y
-6.5
Industry
22.2
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-5.7
Industry
24
vs History
42
vs Industry
32
Median 3Y
1.6
Median 5Y
1.5
Industry
2.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
26
Median 3Y
-1.8
Median 5Y
-1.8
Industry
5.1
Forward
-2.4
vs History
vs Industry
24
Median 3Y
-1.8
Median 5Y
-1.8
Industry
4.7
Forward
-2.4
vs History
vs Industry
27
Median 3Y
-2.3
Median 5Y
-2.3
Industry
6.6
vs History
vs Industry
23
Median 3Y
-2.3
Median 5Y
-2.1
Industry
4.7
vs History
44
vs Industry
26
Median 3Y
3.3
Median 5Y
3.1
Industry
4.7

Multiples Across Competitors

ERAS Competitors Multiples
Erasca Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Erasca Inc
NASDAQ:ERAS
802.7m USD 0 -5.1 -2.7 -2.7
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129B USD 9.6 29.8 26.2 29
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.6B USD 12 -252.2 26.8 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 975 -504 -548.8 -534.2
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.4 22.3 27.8
US
Seagen Inc
F:SGT
39.3B EUR 19 -58.3 -62.8 -56.7
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
US
Erasca Inc
NASDAQ:ERAS
Average P/E: 57.6
Negative Multiple: -5.1
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504 N/A
AU
CSL Ltd
ASX:CSL
36.4
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Erasca Inc
NASDAQ:ERAS
Average EV/EBITDA: 47.8
Negative Multiple: -2.7
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.8 N/A
AU
CSL Ltd
ASX:CSL
22.3
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -62.8 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A
EV/EBIT Multiple
EBIT Growth
US
Erasca Inc
NASDAQ:ERAS
Average EV/EBIT: 69.5
Negative Multiple: -2.7
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.2 N/A
AU
CSL Ltd
ASX:CSL
27.8
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
328.9
N/A

See Also

Discover More
Back to Top